Proteomics International Laboratories Ltd (ASX: PIQ) is pleased to announce that the national rollout of Promarker D and Promarker Eso blood tests, in collaboration with Healius Limited (ASX: HLS) (“Healius”), is scheduled to commence on Monday, 26 October 2026.
Highlights
National rollout of Promarker D and Promarker Eso through Healius, Proteomics International’s exclusive Australian pathology distribution partner, scheduled to commence on Monday, 26 October 2026.
Field sales teams have completed training in both tests, with joint sales and marketing plans agreed to support clinician education, awareness and appropriate referrals.
Systems and operational integration will enable patient blood collection and payment through Healius collection centres.
National rollout of Promarker D and Promarker Eso experience to support commercial release of Promarker®Endo in FY27 Q3 (January–March 2027), subject to clinical deployment and applicable quality, accreditation and regulatory requirements.
View ASX announcement: here